Pharmathen Eyes US Growth As Owner Announces Sale
BC Partners Divests Pharmathen To Swiss-Based Partners Group
With plans to drive continuous innovation in drug administration technology and further implement state-of-the-art production capabilities, Swiss-based private equity Partners Group has announced a deal to acquire long-acting injectables specialist Pharmathen.
You may also be interested in...
Looking back over a busy third quarter in 2021, Generics Bulletin executive editor David Wallace picks out highlights from July to September that include major legal and regulatory developments, multiple firsts in the biosimilars arena, significant M&A activity and our annual ranking of the off-patent sector’s top 50 companies.
Three years after rebranding from Concordia, Advanz Pharma is to be swallowed up by European-focused private equity Nordic Capital.
Private-equity firm BC Partners has struck a deal to acquire a majority stake in Synthon International Holding.